In Brief: Cel-Sci
Cel-Sci: Institutional investors purchase $5 mil. in convertible series B preferred stock, Alexandria, Va.-based Cel-Sci reports Aug. 19. The preferred stock is convertible prior to August 1998. "The financing is set up" to minimize the impact of "the recent decrease in the company's stock price," Cel-Sci says. "Conversion prices will depend mostly on the future stock price." Cel-Sci estimates its $10 mil. in total funding will sustain operations for two years...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth